Insider Selling: Abeona Therapeutics (NASDAQ:ABEO) CFO Sells $99,489.78 in Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) CFO Joseph Walter Vazzano sold 18,666 shares of Abeona Therapeutics stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $5.33, for a total value of $99,489.78. Following the sale, the chief financial officer directly owned 568,560 shares in the company, valued at $3,030,424.80. The trade was a 3.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Abeona Therapeutics Stock Performance

Shares of NASDAQ ABEO opened at $5.16 on Friday. The firm has a market capitalization of $279.62 million, a price-to-earnings ratio of 4.20 and a beta of 1.12. Abeona Therapeutics Inc. has a one year low of $3.93 and a one year high of $7.54. The business has a fifty day simple moving average of $5.08 and a 200 day simple moving average of $5.63. The company has a current ratio of 9.74, a quick ratio of 9.53 and a debt-to-equity ratio of 0.06.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. Sell-side analysts expect that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ABEO. Intech Investment Management LLC grew its position in Abeona Therapeutics by 19.6% during the 3rd quarter. Intech Investment Management LLC now owns 25,176 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 4,127 shares during the last quarter. Creative Planning boosted its stake in Abeona Therapeutics by 43.0% in the second quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 4,305 shares in the last quarter. Ameritas Investment Partners Inc. bought a new stake in shares of Abeona Therapeutics during the second quarter worth $25,000. Legal & General Group Plc acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at $27,000. Finally, Riverwater Partners LLC increased its stake in shares of Abeona Therapeutics by 45.6% in the third quarter. Riverwater Partners LLC now owns 15,857 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 4,963 shares in the last quarter. 80.56% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ABEO has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research note on Monday, October 13th. Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.